Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19*17 is associated with decreased breast cancer risk.

Breast cancer research and treatment - 1 May 2009

Justenhoven Christina, Hamann Ute, Pierl Christiane B, Baisch Christian, Harth Volker, Rabstein Sylvia, Spickenheuer Anne, Pesch Beate, Brüning Thomas, Winter Stefan, Ko Yon-Dschun, Brauch Hiltrud

Abstract excerpt

Cytochrome P450 2C19 (CYP2C19) plays an important role in the metabolism of xenobiotics and drugs and contributes to the catabolism of endogenous substrates like estradiol. Genetic variability impacts expression and activity of CYP2C19 and therefore can influence catabolism of estrogens. In the present study we analyzed the association of three polymorphisms of CYP2C19 namely CYP2C19*2 (CYP2C19_681_G>A,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP2C19

Share to Haplotypes

Share to Oligonucleotide Array Sequence Analysis

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Source

Identifiers

PMID: 18521743
DOI: 10.1007/s10549-008-0076-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19*17 is associated with decreased breast cancer risk.PMID 18521743Read ↗

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.Semantic proximity Read ↗

A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.Semantic proximity Read ↗

Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women.Semantic proximity Read ↗

CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. a HuGE review.Semantic proximity Read ↗

Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.Semantic proximity Read ↗

The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.Semantic proximity Read ↗

Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review.Semantic proximity Read ↗

Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.Semantic proximity Read ↗

Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.Semantic proximity Read ↗

Analysis of CYP17, CYP19 and CYP1A1 Gene Polymorphisms in Iranian Women with Breast Cancer.Semantic proximity Read ↗

Breast Cancer Susceptibility: Meta-Analysis of Cytochrome P450 2C19 (CYP2C19) and Estrogen Receptor-1 (ESR1) Genetic Variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.